Silexion gets Nasdaq bid-price notice after 30 days below $1.00; hearings panel to weigh listing

Silexion Therapeutics Corp

Nasdaq Listing Qualifications staff letter dated September 25, 2026 says SLXN ordinary shares closed below the $1.00 minimum bid for 30 consecutive business days, breaching Listing Rule 5550(a)(2).
Nasdaq's hearings panel will consider the bid price deficiency in deciding whether Silexion may remain listed on the Nasdaq Capital Market.
Nasdaq says the letter has no immediate effect: ordinary shares keep trading as SLXN and listed warrants keep trading as SLXNW.
Warrants to buy ordinary shares carry an exercise price of $15,525.00 per share; ordinary shares have $0.135 par value.
Company says it cannot assure ongoing compliance with the bid price rule or other Nasdaq listing requirements.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.